Compare MT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MT | ILMN |
|---|---|---|
| Founded | 1976 | 1998 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 37.0B |
| IPO Year | 2003 | 2000 |
| Metric | MT | ILMN |
|---|---|---|
| Price | $64.35 | $208.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $77.33 | ★ $261.45 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 3.65 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $8.38 | $6.61 |
| Revenue Next Year | $10.52 | $7.00 |
| P/E Ratio | ★ $15.95 | $58.97 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.67 | $112.65 |
| 52 Week High | $79.68 | $309.35 |
| Indicator | MT | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 35.75 |
| Support Level | $64.27 | $200.01 |
| Resistance Level | $67.56 | $231.81 |
| Average True Range (ATR) | 1.61 | 14.04 |
| MACD | 0.88 | -5.76 |
| Stochastic Oscillator | 77.77 | 12.08 |
ArcelorMittal SA is an integrated steel and mining company. The company's reportable operating segments include North America, Brazil, Europe, India and JVs, Sustainable Solutions, and Mining. It generates maximum revenue from the Europe segment. The Europe segment produces hot-rolled coil, cold-rolled coil, coated products, tinplate, plate, and slab. These products are sold to customers in the automotive, general, and packaging sectors, as well as producing long products consisting of sections, wire rods, rebar, billets, blooms and wire drawing, and tubular products. Geographically, it derives a majority of its revenue from the United States, followed by Brazil, Canada, Mexico, Argentina, and other markets.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.